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 Obesity is a growing problem in the United States, though not a new one. It was estimated that 
over 72 million U.S. adults alone have a diagnosis of obesity. Among all preventable premature deaths, 
obesity ranks as the second leading cause. Contemporary classifications define obesity as a body mass 
index (BMI) greater than or equal to 30. Several common comorbidities are widely present in obese 
populations, particularly hypertension, diabetes, and hyperlipidemia. Among these chronic disease 
states, hypertension has been identified as the most common and earliest identifiable. The purpose of 
this study was to make inferences on the prescribing of antihypertension medications in an obese 
population, as well as the associated cost of said medications. Cerner’s Health Facts Library, a health 
records library that contains de-identified patient information was employed for this study. Structured 
Query Language (SQL) was used to design tables that incorporated all relevant and necessary 
information for analysis of the study question. The results of this study showed that ACE inhibitors were 
the most commonly prescribed blood pressure lowering class of medication in this obese population. Of 
this class, the ACE inhibitor lisinopril was the most commonly prescribed. Lisinopril was also identified as 
the cheapest ACE inhibitor.  
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Chapter 1  
Introduction 
The prevalence of obesity, classified as a BMI greater than 30 (Table 1), has reached epidemic 
proportions. A study by Ogden et al. estimated that over 72 million US adults alone have a diagnosis of 
obesity (Ogden et al. 2007). Additionally, among all preventable premature deaths, obesity ranks as the 
second leading cause, with smoking holding on to the number one spot (Stein & Colditz, 2004). 
However, some experts have predicted that obesity may soon replace smoking as the leading cause of 
preventable deaths in the United States. Since the World Health Organization (WHO) classified obesity 
as a disease, various initiatives have been implemented to attempt to tackle the growing issue of 
obesity. However, the prevalence has not decreased, and therefore, remains an important public health 
agenda (WHO, 2016).  Interestingly, the prevalence of obesity differs by sex, age, and socioeconomic 
status, with a rapid increase in the occurrence of obesity among younger populations and those of lower 
socioeconomic status.  Obesity has been and continues to be a major public health issue both in itself 
and as a result of its association with the development of several chronic comorbidities (NIH, 2006). 
The steady increase in the prevalence of obesity has created a growing need and demand for a 
more in-depth focus on preventable cardiovascular diseases. Such initiatives would target the most 
common comorbidities associated with obesity. Such initiatives would also pay special attention to 
disease states such as diabetes mellitus, hyperlipidemia, and hypertension. This is because obesity is 
associated with an increased incidence of cardiovascular disease, type 2 diabetes mellitus, hypertension, 
stoke, dyslipidemia (hyperlipidemia), osteoarthritis, and some cancers (Burton et al. 2005). Of the top 
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Table 1. Weight Classifications by Body Mass Index (BMI) 
Terminology BMI (kg/m2) Range WHO Classification 
Underweight <18.5 Underweight 
Normal 18.5-24.9 Normal  
Overweight 25.0-29.9 Preobese 
Obesity Class 1 30.0-34.9 Obese Class 1 
Obesity Class 2 35.0-39.9 Obese Class 2 
Obesity Class 3 > 40 Obese Class 3  
 
Background of Problem 
 A study published by Wang and Ling in 2008 looked at the cost and prevalence of obesity in the 
United States and found some interesting results. This study found that the annual spending related to 
obesity and its associated comorbidities was estimated at $315.8 billion dollars in 2010, accounting for 
27.5% of the United States healthcare expenditure.  Additionally, they concluded that costs related to 
being overweight or obese are projected to reach $861 billion dollars by 2030 (Wang and Ling, 2008). 
This is a significant portion of U.S. healthcare cost and therefore warrants a closer analysis. This led us to 
breakdown the numbers and assess the role that medications play in contributing to the rising cost of 
care for obese populations, and any implications that may be revealed by what was find.  
Purpose of Study 
With the idea of the enormous cost associated with care for obese and overweight populations 
in mind, we wanted to determine the role that prescription medications played in contributing to the 
overall cost and burden of obesity on the U.S. healthcare system. This study determined the most 
common comorbid conditions associated with obesity and broke them down further into the most 
common and earliest identifiable comorbid condition. This was found to be hypertension.  The aim of 
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this study was to determine which hypertension medications were most commonly prescribed in obese 
patients, the cost associated with each and to infer how medication cost affects the delivery and quality 
of care administered.  
 
Significance of Study 
 The focus of this study, as mentioned above, is to determine the most frequently, and most 
expensive hypertension medications prescribed. This study is important because the prevalence of 
obesity is at an all time high in the United States and continues to grow. This study breaks down the 
most frequently prescribed hypertension medications and assess the cost associated with each. This is 
significant because hypertension is the most common comorbid condition associated with obesity, as 
well and the earliest identifiable risk factor. By indirectly assessing prescribing, and cost, we can draw 
inferences and make associations between the medications prescribed, disease progression, and 
compare the most updated treatment guidelines with what is actually being prescribed. This type of 
analysis has the ability to generate hypothesis and shed light on any inconsistencies.  
 In addition to the aforementioned, this research has the ability to affect populations at risk for 
obesity. This is important, because the cost associated with obesity in 2010 was at $315.8 billion dollars, 
and it is estimated that the cost will be $861 billion dollars by 2030 (Wang and Ling, 2008). By shedding 
light on cost, and prescribing, and comparing that to current recommended evidence-based treatment 
guidelines, this study can generate discussion on the way hypertension in currently managed in the 
obese. 
Research Questions 
 As mentioned above, the questions that this paper aims to answer are important ones. These 
include determining which hypertension medications are most commonly prescribed (occur the most 
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frequently) and determining which hypertension medications are the most expensive.  To answer these 
questions, this study relied on Cerner’s Health Facts® Database. This database captures and stores de-
identified, longitudinal electronic health record (EHR) patient data, and then aggregates and organizes 
these data into consumable data sets to facilitate analysis and reporting. The data are generated from 
Cerner and non-Cerner participating contributing facilities and go back as far as 2000 (USC, 2017). For 
the purposes of this paper, we will only review the calendars years of 2016 and 2017 due to the lack of 
manpower and resources to analyze larger amounts of data. Oracle will be used to create queries that 
allow us to analyze the data in Cerner’s database. Simple queries will be written that identify the most 
commonly prescribed medications for the time period that we are interested in. This information will be 
broken down further to analyze the cost of each hypertension medication. By doing this, it will allow for 
analysis of prescribing and cost. With this information, inferences can be made regarding the delivery of 
care as well as how evidence-based and appropriate the care is.  
Definition of Terms 
 Antihypertensives – A class of medications used to treat hypertension (high blood pressure). The 
goal of this therapy is to prevent the complications associated with prolonged high blood pressure. 
 Angiotensin Converting Enzyme Inhibitor (ACE Inhibitor) – A class of antihypertensive 
medications that lower blood pressure by inhibiting the enzyme, ACE.    
 Calcium Channel Blocker (CCB) - A class of antihypertensive medications that lower blood 
pressure by antagonizing the movement of calcium through calcium channels.  
 Total Charges - The total charges for an encounter. Total Charges includes both covered and 
non-covered charges. 
 Unit Price - The price per dose for inpatient orders, or the price of the entire quantity for 
outpatient orders. 




 As with every research study, there are limitations. Because this research question relies on 
information entered into an electronic health record, the data is only as accurate as it was entered. 
Inaccurate entries and coding are two limitations of this study. Additionally, not all relevant information 
may have been available for analysis due to clerical entering and editing. Additional limitations include 
the fact that this study only assess the years of 2016 and 2017 leading to a smaller sample size. This may 
limit external validity.     
Chapter 2 
Review of Literature 
 This section will focus on how the literature was obtained, as well as a brief history on the 
current research question, with a focus on past, and present literature. Each article referenced in this 
study will be briefly reviewed and related to the overall purpose of this study.  
 Search engines employed in this literature review included PubMed, Google Scholar, and the 
Cochrane Library. Terms such as “obesity” “hypertension” “comorbidities” “obesity disease burden” and 
“pharmacoeconomics of obesity” were all used to begin the literature search. Of the literature search 
engines above, PubMed provided the most relevant results, and therefore, provided the most articles 
included in this paper. Google Scholar provided the broadest information sources and set a solid 
foundation that allowed for better understanding of the subject. Articles included in this paper were not 
limited by date published. To further narrow the search, articles had to be US-based, of high-quality 
study design, and contain large sample sizes.  No case-controlled studies were included in this paper. 
Once the most relevant articles were identified, they were analyzed for accurateness. Of the top 15 
most relevant articles identified, 2 were studied in a Korean population, 1 included a UK population 
sample, 1 was a poorly designed case study and 1 included a handicap population consisting of 
paraplegics and quadriplegics.  As a result, only 10 articles were included in the final analysis. As 
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mentioned earlier, publication dates were not limited. This was done to provide historical context and 
reference for the researchers and audience. 
 To provide historical reference, literature on the topic of obesity and the disease burden 
associated with it is vast and thorough.  This includes classification of obesity, disease progression, 
associated comorbidities, predisposing factors, prevalence, genetic associations, pharmacoeconomic 
analysis, and medications used to treat, among many others. However, despite all of the research done 
on this topic, there is a limited amount of studies that breakdown the most commonly prescribed 
medications and assess the associated cost and prescribing. Furthermore, there are even fewer studies 
that assess specific classes of medications (i.e. antihypertensives). A 1993 study by Schmieder, Gatzka, 
Schächinger, Schobel, and Rüddel looked at the use of different types of antihypertensives in obesity, 
with the hypothesis that beta blockers are more effective in this population than calcium channel 
blockers. They believed that calcium channel blockers would be more effective in a non-obese 
population (Schmieder et al. 1993). While not identical to this study, this is one of the few studies that 
assess the use of different hypertensive medications in the obese populations. Unfortunately, it is an old 
article. 
 Current literature on this topic is very limited (Table 2). Two of the larger, more complete 
studies, one a randomized controlled trial by Nedogoda et al., and the other being a systemic review by 
Owen and Reisin shed light on this topic and have been referenced numerous times. Outside of the 
studies outlined in Table 2, not many have assessed antihypertensive medications as it pertains to 
prescribing and cost, from an electronic health record such as the Health Facts Database. This is one 
reason that this study is unique. As demonstrated in Table 2, current literature focuses on determining 
which medications are most appropriate and/or effective in obese patients, and treatment of 
hypertension in obesity. 
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Table 2. Relevant Current Literature 
Authors Article Title Population  Year Published 
Owen & Reisin Anti-hypertensive Drug Treatment of 
Patients with and the Metabolic 
Syndrome and Obesity: A Review of 
Evidence, Meta-Analysis, Post hoc and 
Guidelines Publications 
ad hoc studies, prospective 
studies, and guideline 
publications 
2015 
Landsberg et al. Obesity‐Related Hypertension: 
Pathogenesis, Cardiovascular Risk, and 
Treatment 
N/A 2013 
Nedogoda et al. Randomized Trial of Perindopril, 
Enalapril, Losartan and Telmisartan in 
Overweight or Obese Patients with 
Hypertension 
120 overweight or obese 
patients (body mass index 
≥27 kg/m2) with hypertension 
2013 
Schmieder et al. Obesity as a Determinant for Response 






 The purpose of this section is to detail the methods performed and steps taken to complete this 
research project. In this section, the reader can expect to find in-depth statements on the research 
design, the research population, as well as their demographics and how this population was chosen, in-
depth explanations on how data was collected, any collection instruments employed as well as their 
development process, and lastly, an explanation of data analysis. This chapter will be concluded with a 
summary of everything discussed. 
Research Design 
 This study used information entered into Cerner’s Health Facts Library. This library contains a 
plethora of de-identified patient information and allowed for the analysis of the study question.  
Population and Sample Design 
 The purpose of this study was to make inferences on the prescribing of antihypertension 
medications in an obese population via frequency of occurrences in the database, as well as the 
associated cost of these medications. With such a question, the population must meet specific 
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requirements. This study employed an obese population with multiple comorbid conditions. Patients 
were retrospectively selected based on records from Cerner’s Health Facts Database. Those selected 
had a BMI of 30 or greater, were 18 years or older, and had to have a clinical diagnosis of hypertension.  
Patients also had to be on at least one prescription antihypertensive medication.  Patients were 
excluded if they had a diagnosis of obesity, but no history of hypertension, had a diagnosis of 
hypertension but no prescription antihypertensive medications, or had an BMI greater than 70. This BMI 
cutoff was based on the National Institute of Health’s BMI chart that includes BMIs through 60. While a 
BMI greater than 70 is not uncommon, BMIs that high are more prone to charting errors. This 
population was selected because they provided the most relevant characteristics for the question at 
hand. This population would allow for answering of the question as well as further analysis of any post-
analysis questions. Patient demographic breakdown is included in Table 3. 
 
Table 3. Patient Demographics 
Age & BMI Race and Ethnicity (n=39,844) 
Average Age 59 Caucasian  90.8% 
Most Common Age 67 African American 5.4% 
Average BMI 34 Asian 0.065% 
Most Common BMI 30.7 Pacific Islander 0.005% 
Gender Native American 3.1% 
Male 41.1% Asian/Pacific Islander 0.07% 
Female 58.8% Other/Unknown/Not Mapped 0.51% 
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Data Collection  
 Data for this study was collected retrospectively via Cerner’s Health Facts Database. Structured 
Query Language (SQL) was used to design tables that incorporated all relevant and necessary 
information. The final table included age, total charges (the cost for the encounter, which includes 
covered and non-covered charges), BMI, year, patient sk (a unique blinded person identifier), 
medication brand and generic names, and drug classification. Information from this table allowed for 
the identification of hypertensive medications.  
Data Collection Instrument  
 Cerner’s Health Facts Database was employed for the purposes of data collection in this study. 
Structured Query Language was used to create queries and tables that contained all relevant and 
necessary information  
Results 
 This purpose of this chapter is to discusses the results of this study as well as the generalizability 
of said results.  
 In this study, angiotensin converting enzyme (ACE) inhibitors were identified as the most 
common antihypertensive medication prescribed (it occurred the most often) to this obese population. 
According to data released from the Department of Pharmaceutical Sciences within the College of 
Pharmacy at Larkin University in conjunction with the Centers for Disease Control and Prevention 
Institute, it is also the most common blood pressure lowering medication prescribed to non-obese 
populations as well (Figure 1).  
The average age of this population was 59, with an average BMI of 34, classifying this population 
as obesity class 1. When all ACE inhibitors were examined, lisinopril (Prinivil®, Zestril®) occurred the 
most often. This insinuates that, in this population, lisinopril was prescribed the most often. Other ACE 
AN ASSESSMENT OF UTILIZAITON OF PRESCRIPTION 
15 
 
inhibitors included enalapril, accupril, and captopril. When cost of each agent was assessed, the total 
charges was highest when associated with lisinopril. Because lisinopril is prescribed more than other 
ACE inhibitors, it has a greater chance of being associated with a more expensive encounter, when 
compared to other similar medications. We do not believe that the addition of lisinopril contributes to a 
more expensive encounter. This hypothesis is consistent with what was seen when unit price was 
analyzed. When unit price was assessed, lisinopril was the cheapest, on average (Table 6).  
 When the results of this study was compared to The American College of Cardiology and 
American Heart Association (ACC/AHA) Hypertension Treatment Guidelines, it appears that the study 
population received appropriate and evidence based care. These guidelines are used nationally and 
internationally and set the standards for care of patients with hypertension. They recommend the use of 
an ACE inhibitor, calcium channel blocker, thiazide diuretic, or angiotensin receptor blocker first line. As 
mentioned earlier, ACE inhibitors were the most common antihypertensive in our population. When 
combination first line agents were assessed the following in Table 4 was observed. 
   
Table 4. Combination First Line Antihypertensive Agents 
ACE-I + Thiazide ACE-I + CCB 
20% 12% 
Most Commonly Prescribed Anti-Hypertensive In US (2018) 
1. Lisinopril (ACE-I) 
7. Amlodipine (CCB) 
11. Hydrochlorothiazide (Thiazide) 
12. Losartan (ARB) 
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Figure 1. Top 40 Most Commonly Prescribed Drugs in the United States 
 
 
Table 6. Unit Price of ACE Inhibitors 








Conclusions and Recommendations  
 This chapter will reiterate the purpose of the study as well as highlight important points and 
connect supporting arguments. 
 




 The results of this study, mentioned above, found that the ACE inhibitor lisinopril was the most 
commonly prescribed antihypertensive in the study populations. This is what is also seen outside of the 
study population in the real world. In fact, lisinopril was the most commonly prescribed medication in 
the United States in 2018 (Figure 1).  ACE inhibitors were likely the most prescribed agent due to the 
numerous benefits outside of blood pressure lowering. In fact, in addition to lowering blood pressure, 
they also help protect the kidneys, decrease the risk of heart attack, decrease the risk of stroke, 
decrease all-cause mortality by 10% and decrease cardiovascular mortality by 12%. Additionally, for 
individuals who have had a previous heart attack or stroke, ACE inhibitors have been shown to decrease 
reoccurrence. Why lisinopril in particular was the most commonly occurring ACE inhibitor is likely due to 
cost. When unit price was analyzed, it was cheapest for lisinopril (Table 6). However, this same analysis, 
when applied to the other ACE inhibitors, didn’t hold true; number of occurrences wasn’t positively 
correlated with cost.  There are likely other underlying factors that are at play and further analysis is 
warranted to determine this lack of correlation. Considering the results and the conclusion, it does not 
appear that hypertension medications are contributing much to the overall healthcare expenditure. It 
should also be noted, however, that this information is a snapshot in time. Therapy progression and 
adverse effects that led to medication discontinuation, among other things, is unknown. It is important 
to keep this in mind when definitively determining therapy appropriateness.  
Recommendations 
 ACE inhibitors are a class of antihypertensive medications that offer a range of benefits outside 
of lowering blood pressure. They are currently some of the most commonly prescribed blood pressure 
lowering medications. Based on the results and conclusions of this study, ACE inhibitors are being 
prescribed preferentially to other similar medications and should continue to be prescribed as such, 
given the cost and aforementioned benefits. 
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 Future studies should examine prescribing of DM and HLD medications in the obese with a 
similar focus of this study. This is timely and appropriate as there have been surges in the price of 
insulin, used to treat DM, in recent months. Additionally, cost should be assed based on region of the 
country. It has been well established that the south has higher rates of obesity than the west and 
northeast.  Other areas of interest can focus on determining formulary status and figuring out how 
formulary designations affect guideline prescribing.  
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